Investor News Fresenius Medical Care AG & Co. KGaA Investor Relations Else-Kr ner-Str. 1 D-61352 Bad Homburg Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir@fmc-ag.com North America: Te

Fresenius Medical Care Acquires Renal Solutions, Inc.

Medical Care acquires technology to advance home hemodialysis and

create a platform for development of a wearable kidney.

Medical Care AG & Co. KGaA today

announced that it has acquired Renal Solutions, Inc. (RSI). The acquisition

agreement provides for total consideration of up to $190 million, consisting of

$100 million at closing, $60 million after the first year, and up to $30

million in milestone payments over the next three years. RSI had approximately

$10 million of net debt outstanding at closing.

is currently commercializing the Allient Sorbent Hemodialysis System, which is

returning sorbent-based technology (SORB) to the dialysis field. The SORB

cartridge has a long market history in hemodialysis with over 6 million

cartridges sold. As the innovator in the SORB technology field, RSI holds key

patents and other intellectual property worldwide related to the SORB

sorbent technology purifies tap water to dialysate quality and allows dialysate

to be regenerated. This reduces the water volume requirement for a typical

hemodialysis treatment from 120 liters / 37 gallons of reverse osmosis water to

just 6 liters / 1.5 gallons of drinking water per treatment.

combination of Fresenius Medical Care s leading hemodialysis technology and the

SORB technology will provide a platform for superior home products and

therapies. Furthermore, the significant reduction of dialysate through SORB

technology is one major step towards miniaturization a pre-requisite for the

wearable kidney concept which could benefit certain patients and complement

clinical-based therapy.

Medical Care sees the current market size of the Home Therapy Market

(Peritoneal Dialysis and Home Hemodialysis) at about $2 billion representing

approximately 11% of the overall worldwide dialysis market. The Company

believes the Home Therapy market has the potential to grow to $4 billion within

the next 10 years. Fresenius Medical Care has a market share in this market

segment of approximately 30%. Home hemodialysis (HHD)

has been a niche market for many years but with growing attention in recent

past. With increased access to adequate therapy, the Company projects the

number of HHD patients in North America could grow from about 0.5% at the end

of 2006 to approximately 4% of the patient population in the next

Ben Lipps, Chief Executive Officer of Fresenius Medical Care commented, The

acquisition of RSI is an important step to advance the technology required for

strong future growth in this field. The combination offers us the long-term

opportunity to extend our leadership to home and acute dialysis products.

Furthermore, by combining our equipment and membrane technology with the SORB

technology, we can provide innovative solutions in the future such as a

possible wearable kidney. With this acquisition, Fresenius Medical Care expects

to increase its annual R&D spending by approximately $10 million starting

in 2008. Our mid-term financial targets for the years 2007 through 2010 remain

Medical Care is the world s largest integrated provider of products and

services for individuals undergoing dialysis because of chronic kidney failure,

a condition that affects more than 1,500,000 individuals worldwide. Through its

network of 2,221 dialysis clinics in North America, Europe, Latin America,

Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to

172,227 patients around the globe. Fresenius Medical Care is also the world s

leading provider of dialysis products such as hemodialysis machines, dialyzers

and related disposable products. Fresenius Medical Care is listed on the

Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS,

For more information about

Fresenius Medical Care visit the Company s website at www.fmc-ag.com.

For more information about

Renal Solutions Inc. visit the Company s website at www.renalsolutionsinc.com.

This release contains forward-looking

statements that are subject to various risks and uncertainties. Actual results

could differ materially from those described in these forward-looking

statements due to certain factors, including uncertainties in the development

of the home dialysis market, the ability to develop and commercialize

technological innovations, changes in business, economic and competitive

conditions, regulatory reforms, foreign exchange rate fluctuations,

uncertainties in litigation or investigative proceedings, and the availability

of financing. These and other risks and uncertainties are detailed in Fresenius

Medical Care AG & Co. KGaA s reports filed with the U.S. Securities and

Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not

undertake any responsibility to update the forward-looking statements in this